Updated:
NeuroPace
NeuroPace, led by CEO Joel Becker, markets the only FDA-approved closed-loop brain-responsive neurostimulation device for drug-resistant epilepsy.
NeuroPace
NeuroPace was founded in 1997 by Stanford researchers who recognized that epilepsy surgery and medication left a large treatment gap for patients with focal onset seizures. The company developed the RNS System, an implantable device that monitors brain activity continuously and delivers targeted electrical pulses only when it detects abnormal patterns. CEO Joel Becker, who joined in 2015 and assumed the top role in 2020, has steered the firm through its 2021 IPO on Nasdaq (ticker: NPCE) and expanded the clinical evidence base supporting the technology. The RNS System distinguishes itself from traditional open-loop deep brain stimulation devices by responding to the patient's own brain signals rather than delivering constant or scheduled stimulation. NeuroPace markets the device to epilepsy centers across the United States, where roughly 3.4 million people live with epilepsy and approximately one-third have drug-resistant forms. The firm generates revenue directly from device implants, lead replacements, and the cloud-based patient data management platform that neurologists use to review electrographic seizure data captured by the implant. Reimbursement comes primarily through commercial payors and Medicare. NeuroPace operates as a publicly traded medical device company headquartered in Mountain View. The firm employed 163 people as of its most recent annual filing and reported $56.8 million in 2023 revenue, up from $40.4 million in 2021. The company's installed base surpassed 5,000 patients as of early 2024, providing a recurring data stream and established referral pathways within the U.S. comprehensive epilepsy center network. In January 2022, NeuroPace received FDA 510(k) clearance for broader MRI labeling, which expanded the eligible patient population — a regulatory milestone that removed a prior commercial limitation. NeuroPace's structural advantage lies in a regulatory moat: no direct competitor has a prospectively studied closed-loop seizure intervention platform with the same longevity of long-term safety and effectiveness data. The proprietary detection algorithms, refined over 25 years across thousands of patient-years of intracranial EEG data, create a switching cost for clinical centers that have built protocols around the RNS programming workflow. While the total addressable market for drug-resistant epilepsy is constrained by surgical candidacy rates, the absence of a direct replacement technology makes the firm's position defensible within that niche.
General information
Firm type
other
Year founded
1997
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Mountain View
Corporate office
Mountain View, CA, United States
Principals
Joel Becker
President and Chief Executive Officer
Sector focus
Frequently asked questions
What is the RNS System and how does it differ from standard neurostimulators?
The RNS System is an implantable cranial neurostimulator that detects abnormal electrocorticographic activity in real time and delivers responsive electrical stimulation to terminate or prevent seizures. It operates closed-loop, unlike open-loop devices that provide continuous or scheduled stimulation regardless of brain state. The system also records patient EEG data for clinician review, turning the implant into a diagnostic tool that informs medication adjustments.
How does NeuroPace generate revenue?
Revenue comes primarily from the sale of implantable RNS neurostimulators, depth and cortical strip leads, and replacement procedures when batteries near end of life. The company also earns recurring income from proprietary cloud-based software used by clinicians to access and analyze patient seizure data. Payors include commercial insurers and Medicare. In 2023, the firm reported $56.8 million in total revenue.
Who runs investment decisions at NeuroPace?
NeuroPace is a publicly traded medical device company, not a family office or investment firm. Capital allocation decisions rest with management and the board of directors. The firm does not manage external capital, nor does it operate as a family office or asset manager. Joel Becker serves as President and CEO.
Is NeuroPace a single family office or does it operate more like a venture firm?
Neither. NeuroPace is a commercial-stage, Nasdaq-listed medical device company founded in 1997. It develops, manufactures, and sells the RNS System directly to hospitals and epilepsy centers. It does not make fund investments, manage outside capital, or operate as a family office. It is sometimes confused with wealth management entities due to the -Pace suffix, but its business is medical technology.
What regulatory approvals does the RNS System hold?
The RNS System received an FDA premarket approval (PMA) in November 2013 for adults with drug-resistant focal onset seizures. In January 2022, the FDA cleared a 510(k) for expanded MRI labeling, allowing certain scans without removing the device. The firm is also approved in specific European markets, though U.S. sales dominate revenue. No competing closed-loop seizure device holds the same longevity of regulatory authorization.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: